| Title: |
Acute Stroke Management in Türkiye: Intravenous Tissue Plasminogen Activator and Thrombectomy NöroTek: Türkiye Neurology Single Day Study |
| Authors: |
TOPÇUOĞLU, MEHMET AKİF; ÖZDEMİR, ATİLLA ÖZCAN; ARSAVA, ETHEM MURAT; Gunes, Aygul; AYKAÇ, ÖZLEM; Gencer, Elif Sarionder; Cabalar, Murat; Yayla, Vildan; Erdogan, Haci Ali; Erdogan, Mucahid; Acar, Zeynep Ozdemir; GİRAY, SEMİH; KABLAN, YÜKSEL; Tanriverdi, Zeynep; Tekan, Ulgen Yalaz; Asil, Talip; Akpinar, Cetin Kursad; Yurekli, Vedat Ali; Acar, Bilgehan; ŞİRİN, HADİYE; GÜLER, AYŞE; Ocek, Levent; ÇETİNER, MUSTAFA; NAZLIEL, BİJEN; BATUR ÇAĞLAYAN, HALE ZEYNEP; Ongun, Nedim; EREN, Alper; Arlier, Zulfikar; Cenikli, Utku; GÖKÇE, MUSTAFA; Bavli, Songul; YAKA, ERDEM; ÖZKUL, AYÇA; Degirmenci, Bahar; Aluclu, Ufuk; TOGAY IŞIKAY, CANAN; Aslanbaba, Eda; SORGUN, MİNE HAYRİYE; AYTAÇ, EMRAH; AY, HALİL; Kunt, Refik; Senadim, Songul; Unsal, Yaprak Ozum; Eskut, Neslihan; ALİOĞLU, ZEKERİYA; Yilmaz, Arda; Genc, Hamit; Yilmaz, Ayse; Milanoglu, Aysel; Gurkas, Erdem; Degirmenci, Eylem; Bektas, Hesna; Ilgezdi, Irem; BİLGİÇ, ADNAN BURAK; Akyol, Senol; Gungor, Levent; Kale, Nilufer; Coban, Eda; YEŞİLOT, Nilüfer; EKİZOĞLU TURGUT, Esme; Kizek, Ozgu; Kursun, Oguzhan; KAYIM YILDIZ, ÖZLEM; BOLAYIR, ASLI; Kisabay, Aysin; Bastan, Birguel; Acar, Zeynep; Niflioglu, Buket; Guven, Bulent; KAYA, Dilaver; AFSAR, NAZİRE; Yazici, Duran; Toplutas, Eren; Ozkan, Esra; Ilik, Faik; Ince, Fatma Birsen; Buyukserbetci, Gulseren; Onder, Halil; KARADELİ, HASAN HÜSEYİN; KOZAK, HASAN HÜSEYİN; Demirbas, Hayri; MİDİ, İPEK; Aydin, Isa; Epceliden, M. Tuncay; Atmaca, Murat Mert; BAKAR, HACI MUSTAFA; Sen, Mustafa; TURGUT, NİLDA; Keskin, Onur; Akdogan, Ozlem; Emre, Ufuk; Bilgili, Ozlem; Sirinocak, Pinar Bekdik; YEVGİ, Recep; Akkas, Sinem Yazici; Yoldas, Tahir; Duman, Taskin; Ozel, Tugba; ÜNAL, ALİ; DORA, BABÜR; Atasoy, Tugrul; ÇİNAR, BİLGE PİRİ; Demir, Tulin; DEMİR, TURGAY; Can, Ufuk; Aslan, Yildiz; Bas, Demet Funda; Sener, Ufuk; Yilmaz, Zahide; Bozdogan, Zehra; ÖZDEMİR, GÖKHAN; Krespi, Yakup; ÖZTÜRK, ŞEREFNUR; BAYDEMİR, RECEP; AKCAKOYUNLU, MERVE |
| Publication Year: |
2023 |
| Collection: |
Erciyes University Research Information System |
| Description: |
Objective: To reveal the profile and practice in patients with acute stroke who received intravenous tissue plasminogen activator (IV tPA) and/or neurointerventional therapy in Turkiye. Materials and Methods: On World Stroke Awareness Day, May 10, 2018, 1,790 patients hospitalized in 87 neurology units spread over 30 health regions were evaluated retrospectively and prospectively. Results: Intravenous tPA was administered to 12% of 859 cases of acute ischemic stroke in 45 units participating in the study. In the same period, 8.3% of the cases received neurointerventional treatment. The rate of good prognosis [modified Rankin score (mRS) 0-2] at discharge was 46% in 83 patients who received only IV tPA [age: 67 +/- 12 years; National Institutes of Health Stroke Scale (NIHSS): 12 +/- 6; hospital stay, 24 +/- 29 days]; 35% in 51 patients who underwent thrombectomy (MT) alone (age: 64 +/- 13 years; NIHSS: 14.1 +/- 6.5; length of hospital stay, 33 +/- 31 days), 19% in those who received combined treatment (age: 66 +/- 14 years; NIHSS: 15.6 +/- 5.4; length of hospital stay, 26 +/- 35 days), and 56% of 695 patients who did not receive treatment for revascularization (age: 70 +/- 13 years; NIHSS: 7.6 +/- 7.2; length of hospital stay, 21 +/- 28 days). The symptom-to-door time was 87 +/- 53 minutes in the IV treatment group and 200 +/- 26 minutes in the neurointerventional group. The average door-to-needle time was 66 +/- 49 minutes in the IV tPA group. In the neurothrombectomy group, the door-to-groin time was 103 +/- 90 minutes, and the TICI 2b-3 rate was 70.3%. In 103 patients who received IV tPA, the discharge mRS 0-2 was 41%, while the rate of mRS 0-1 was 28%. In 71 patients who underwent neurothrombectomy, the mRS 0-2 was 31% and mRS 0-1 was 18%. The door-to-groin time was approximately 30 minutes longer if IV tPA was received (125 +/- 107 and 95 +/- 83 minutes, respectively). Symptomatic bleeding rates were 4.8% in IV recipients, 17.6% among those who received only MT, and 15% in combined therapy. Globally, the ... |
| Document Type: |
article in journal/newspaper |
| Language: |
English |
| DOI: |
10.4274/tnd.2023.70292 |
| Availability: |
https://doi.org/10.4274/tnd.2023.70292; https://avesis.erciyes.edu.tr/publication/details/c709a0ea-144a-41a4-8666-5141f4dc5e6a/oai |
| Rights: |
info:eu-repo/semantics/openAccess |
| Accession Number: |
edsbas.24ECC7CC |
| Database: |
BASE |